U.S., Sept. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07187947) titled 'Cardiovascular Health of Transgender Individuals During the Gender-affirming Pathway' on Aug. 29.
Brief Summary: Gender incongruence, now classified in ICD-11 as a "marked and persistent incongruence between an individual's experienced gender and the gender assigned at birth," is managed in dedicated, multidisciplinary centres that coordinate psychological support with medical-surgical care.
Gender-affirming hormone therapy (GAHT) is central to this care pathway. In particular, masculinising GAHT for people assigned female at birth (AFAB) relies mainly on testosterone, and feminising or demasculinising GAHT for people assigned mal...